Bookedited by Jürgen Moll, Riccardo Colombo.
Contents:
The path to oncology drug target validation : an industry perspective
Identification of aptamers as specific binders and modulators of cell-surface receptor activity
The design and structure-functional properties of DNA-based immunomodulatory sequences
SiRNA design principles and off-target effects
Western blot evaluation of siRNA delivery by ph-responsive peptides
High-throughput RNAi screening for the identification of novel targets
Integration of RNAi and small molecule screens to identify targets for drug development
CellProfiler and KNIME : Open source tools for high content screening
PARP inhibition as a prototype for synthetic lethal screens
Structure-based target druggability assessment
Validating pharmacological disruption of protein-protein interactions by acceptor photobleaching FRET imaging
Systematic analysis of complex signal transduction pathways using protein fragment complementation assays
Reverse phase protein microarrays and their utility in drug development
A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization
Two-dimensional vs. Three-dimensional in vitro tumor migration and invasion assays
Tumor spheroid-based migration assays for evaluation of therapeutic agents
The neurosphere assay applied to neural stem cells and cancer stem cells
Genetically engineered animal models for in vivo target identification and validation in oncology
Target validation in mice by constitutive and conditional RNAi
In vivo target validation by inducible RNAi in human xenograft mouse models
Bright-field in situ hybridization methods to discover gene amplifications and rearrangements in clinical samples
Combined microRNA in situ hybridization and immunohistochemical detection of protein markers.